Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

Update Il y a 4 ans
Reference: EUCTR2008-003079-32

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

- To continue to provide chlorambucil to subjects randomized to the chlorambucil arm and aged ≥ 65 and < 81 years of age up to 13 cycles (approximately 12 months), at the discretion of the Investigator - To compare the long term safety of lenalidomide versus chlorambucil in elderly CLL patients


Inclusion criteria

  • FIRST-LINE THERAPY FOR PREVIOUSLY UNTREATED ELDERLY PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA